Bortezomib resistance in multiple myeloma is associated with increased serine synthesis

BACKGROUND: The proteasome inhibitor bortezomib (BTZ) is successfully applied in the treatment of multiple myeloma, but its efficacy is restricted by the wide-spread occurrence of resistance. Metabolic alterations play an important role in cancer development and aid in the cellular adaptation to pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaal, Esther A., Wu, Wei, Jansen, Gerrit, Zweegman, Sonja, Cloos, Jacqueline, Berkers, Celia R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5575874/
https://www.ncbi.nlm.nih.gov/pubmed/28855983
http://dx.doi.org/10.1186/s40170-017-0169-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5575874/
https://www.ncbi.nlm.nih.gov/pubmed/28855983
http://dx.doi.org/10.1186/s40170-017-0169-9

Ejemplares similares